设为首页         

资讯内容 Content

[ESC2010]Sanjit Jolly ESC 2010 Interview
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2010/10/13 11:49:38    加入收藏
 关键字:Sanjit Jolly   STE-ACS   OASIS 5研究  磺达肝癸钠 依诺肝素 

    <International Circulation>:  New anticoagulants such as direct thrombin inhibitors and factor Xa inhibitors are now in use in the clinic. In your opinion, what are the criteria for the best anticoagulation therapy?

  《国际循环》:新的抗凝药物如直接凝血酶抑制剂和Xa因子抑制剂目前已在临床中应用。在您看来,最佳抗凝治疗的标准是什么?

    Prof. Jolly: What the fondaparinux story has told us is that you can have a drug with similar efficacy but improved safety. That is an important goal for these new therapies. If you can reduce bleeding or have a very safe drug then you are much more likely to be successful in the long run.

    Jolly教授:磺达肝癸钠的故事告诉我们的是,你可以有一种有效性相似但安全性改善的药物。对这些新的治疗方法来说,这是一个重要的目标。如果你能减少出血或者有一种非常安全的药物,那么从长远来看,你更有可能获得成功。



上一页  [1]  [2]  [3]  

   评论发言          
 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved